Market News Latest

Excessive Daytime Sleepiness Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – Avadel, BenevolentAI Bio, Theranexus, Bioprojet Pharma, Jazz Pharma, and Others

 Breaking News
  • No posts were found

Excessive Daytime Sleepiness Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies – Avadel, BenevolentAI Bio, Theranexus, Bioprojet Pharma, Jazz Pharma, and Others

May 02
20:00 2022
Excessive Daytime Sleepiness Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - Avadel, BenevolentAI Bio, Theranexus, Bioprojet Pharma, Jazz Pharma, and Others
Delveinsight Business Research LLP
DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Excessive Daytime Sleepiness Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Excessive Daytime Sleepiness market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Excessive Daytime Sleepiness Market

Excessive Daytime Sleepiness: An Overview

Excessive Daytime Sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. EDS is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, and psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. 

According to the National Sleep Foundation (NSF), as many as 20% of people experience EDS, making it the number one complaint of those who visit sleep clinics for treatment. Daytime sleepiness is not a disorder itself but a symptom of conditions that can have serious health effects, such as obstructive sleep apnea or narcolepsy, or a side effect of certain medications or poor sleep habits.

Excessive Daytime Sleepiness Market Key Facts

  • In 2017, the highest cases of Excessive Daytime Sleepiness were diagnosed in the US, in comparison to EU-5 and Japan.

  • Among the European countries, Germany had the highest diagnosed prevalent population of Excessive Daytime Sleepiness with 590,800+ cases, followed by France which had a diagnosed prevalent population of 487,100+ in 2017.

  • Among the EU-5 countries, France ranked second in terms of diagnosed prevalent population of EDS.

  • As per the DelveInsight analysis, it is observed that Japan has the second-highest diagnosed prevalent population of EDS, among 7MM. Japan accounts for approximately 22.40% of the total diagnosed prevalent cases in the 7MM.

  • In 2017, the diagnosed Excessive Daytime Sleepiness prevalent population in the United States was 2,960,500+.

Excessive Daytime Sleepiness Market

Excessive Daytime Sleepiness (EDS) market size is expected to grow by factors like the increase in the patient pool due to a rise in the prevalence of underlying medical conditions and the expected entry of emerging therapies in the coming years.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Excessive Daytime Sleepiness market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Excessive Daytime Sleepiness market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Excessive Daytime Sleepiness Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

Excessive Daytime Sleepiness Therapeutics Analysis

Companies across the globe are diligently working toward the development of novel therapies for EDS with a considerable amount of success over the years. 

Some of the key companies in the Excessive Daytime Sleepiness (EDS) Market include:

  • BenevolentAI Bio

  • Theranexus

  • Bioprojet Pharma

  • Avadel Pharmaceuticals

  • Jazz Pharmaceuticals

  • Axsome Therapeutics

  • Harmony Biosciences

And many others. 

Excessive Daytime Sleepiness (EDS) Therapies covered in the report include:

  • BEN-2001

  • FT218

  • AXS-12 (Reboxetine)

  • Xywav (JZP-258) for EDS in IH

  • Wakix (Pitolisant) for EDS in OSA

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – 
https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Excessive Daytime Sleepiness Competitive Intelligence Analysis

4. Excessive Daytime Sleepiness Market Overview at a Glance

5. Excessive Daytime Sleepiness Disease Background and Overview

6. Excessive Daytime Sleepiness Patient Journey

7. Excessive Daytime Sleepiness Epidemiology and Patient Population

8. Excessive Daytime Sleepiness Treatment Algorithm, Current Treatment, and Medical Practices

9. Excessive Daytime Sleepiness Unmet Needs

10. Key Endpoints of Excessive Daytime Sleepiness Treatment

11. Excessive Daytime Sleepiness Marketed Products

12. Excessive Daytime Sleepiness Emerging Therapies

13. Excessive Daytime Sleepiness Seven Major Market Analysis

14. Attribute Analysis

15. Excessive Daytime Sleepiness Market Outlook (7 major markets)

16. Excessive Daytime Sleepiness Access and Reimbursement Overview

17. KOL Views on the Excessive Daytime Sleepiness Market.

18. Excessive Daytime Sleepiness Market Drivers

19. Excessive Daytime Sleepiness Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/excessive-daytime-sleepiness-eds-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Stereotactic Surgery Devices Market

Global Stereotactic Surgery Devices Market is projected to grow at a CAGR of 5.37% during the forecast period from 2021 to 2026. Some of the key companies in the Stereotactic Surgery Devices Market include Elekta, Accuray Incorporated, Ion Beam Applications, Mevion Medical Systems, Varian Medical Systems, Inomed Medizintechnik, adeor medical, Bramsys Indústria e Comércio, Micromar, Mizuho Medical, Shinva Medical Instrument, Panacea Medical Technologies, Sumitomo Heavy Industries, Hitachi Co. Ltd, and others.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/